

**ASX Release – Company Announcement**

27 May 2026

**Nufarm HY26 results presentation**

Attached is Nufarm Limited's (ASX:NUF) (**Nufarm**) HY26 results presentation which will be delivered by CEO, Rico Christensen and CFO, Brendan Ryan to investors via audio webcast at 10:00am AEST today.

Pre-registration link: <https://s1.c-conf.com/diamondpass/10054080-hu7y6t.html>

Webcast link: <https://webcast.openbriefing.com/nuf-hyr-2026/>

An archived version will be available at <http://www.openbriefing.com/OB/6189.aspx> on demand and on the Nufarm website later in the day.

- ends -

**Authorised by**

Kate Hall  
Company Secretary

**Investor contact**

Grant Saligari - General Manager Investor  
Relations and Corporate Development  
[grant.saligari@nufarm.com](mailto:grant.saligari@nufarm.com)

**About Nufarm**

Nufarm is a global agricultural innovator providing crop protection and seed technology solutions to help our customers grow a better tomorrow. Established over 100 years ago, it is listed on the Australian Securities Exchange (ASX:NUF) with its head office in Melbourne, Australia. Nufarm is the first company to develop and commercialise plant based omega-3 and has developed and commercialised advanced bioenergy feedstock technology.

For personal use only

# Nufarm FY26 Half Year Results



# Disclaimer

## General

This presentation has been prepared by Nufarm Limited. The information contained in this presentation is for informational purposes only as at the date of this presentation on 27 May 2026. The information contained in this presentation is not investment or financial product advice & is not intended to be used as the basis for making an investment decision. The presentation is not intended (nor does it) constitute an offer or invitation by or on behalf of Nufarm Limited, its subsidiaries, or any other person to subscribe for, purchase or otherwise deal in any securities, nor are they intended to be used for the purpose of or in connection with any offers or invitations to subscribe for, purchase or otherwise deal in any securities. This presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person.

## Forward looking statements

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions & conclusions contained in this presentation. To the maximum extent permitted by law, none of Nufarm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation.

This presentation includes certain forecasts, outlook statements, prospects or returns, & other forward looking statements that are based on information & assumptions known to date & are subject to various risks & uncertainties including (without limitation) changes in product demand, the timing & success of new product launches, decisions by regulatory authorities regarding approval & ongoing registration of our products, operational changes, difficulties or delays in manufacturing, third party supply interruptions, weather volatility, cyberattack/unauthorised access, the loss of key personnel, safety incidents, environmental damage, product contamination & quality, compliance breaches, litigation or government investigations, loss of or infringement of the company's intellectual property, infringement of third party intellectual property, global economic & geo-political uncertainty & conflict including in the Middle East, energy security & inflation including increases in costs of goods, commodity price & market selling price volatility, access to finance, foreign exchange exposure & the effect of economic conditions generally. Actual results, performance or achievements may be significantly different from those expressed in, or implied by, these forward looking statements. Such forward looking statements are not guarantees of future performance. Many of the known & unknown risks & uncertainties impacting these forward looking statements are beyond the control of Nufarm Limited. Further information is contained in Nufarm's 2025 Annual Report which is available at Nufarm's corporate website. Accordingly, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of any forward looking statements contained in this presentation.

Before making an investment decision, you should consider, with or without the assistance of a financial advisor, whether an investment is appropriate in light of your particular investment needs, objectives & financial circumstances. Past performance is no guarantee of future performance.

## Non-IFRS information

Nufarm Limited results are reported under International Financial Reporting Standards (IFRS) including Underlying EBIT & Underlying EBITDA which are used to measure segment performance. The presentation also includes certain non-IFRS measures including Underlying net profit after tax & Gross profit margin. These measures are used internally by management to assess the performance of our business, make decisions on the allocation of our resources & assess operational management. Non-IFRS measures have not been subject to audit or review. Certain figures may be subject to rounding differences. Refer to Appendices for the definitions of non-IFRS information & a reconciliation of Underlying EBIT & Underlying EBITDA to Operating profit. All market share information in this presentation is based on management estimates based on internally available information unless otherwise indicated. All amounts are in Australian dollars unless otherwise stated.

# CEO Overview

Rico Christensen


For personal use only

# Strong first half result - FY26 outlook reaffirmed

Improved earnings and cashflow and reduced leverage.

Outlook for FY26 uEBITDA and Leverage 2.0x by end of FY26 reaffirmed.

For personal use only



Refer to appendix for definition of financial terms

# Delivering on the priorities set for FY26

Focus on profitable growth, disciplined capital allocation and free cash generation

## FY26 Priorities

As stated in November 2025<sup>1</sup>

**Cost and  
capital  
discipline**

**Drive profitable  
growth in Crop  
Protection**

**Deliver on  
reprioritised  
Seeds strategy**

## Progress in 1H

- \$193m y/y improvement in free cash flow
- 20% reduction in leverage
- Capex reduction – on target for <\$200m FY26
- Flat operating expenses
  
- 6% y/y constant currency uEBITDA growth
- 1.6ppt margin expansion
- Improved earnings quality through better mix and cost discipline.
  
- Delivering on earnings opportunity in Hybrid Seeds, with 7% growth in uEBITDA
- Strengthened strategic partnership with bp.
- Reduced cash costs in omega-3

1. Nufarm FY25 Full Year Result, page 22, FY26 Priorities

# Crop Protection

Improved earnings quality and margin expansion driven by mix and cost discipline

CROP PROTECTION (\$m)	HY26	HY25 <sup>1</sup>	Change y/y
uEBITDA	223	216	3%
uEBITDA (Constant Currency)	230	216	6%
<b>APAC</b>			
Revenue	403	461	(13)%
uEBITDA	55	65	(15)%
uEBIT	47	56	(16)%
<b>NORTH AMERICA</b>			
Revenue	583	638	(9)%
uEBITDA	55	56	(1)%
uEBIT	36	35	1%
uEBITDA (USD)	39	35	11%
<b>EUROPE</b>			
Revenue	485	498	(3)%
uEBITDA	113	95	19%
uEBIT	64	48	33%
uEBITDA (EUR)	67	57	17%

## Crop Protection

- 1.6ppt margin expansion driven by cost discipline and improved product mix - reduced exposure to lower-margin products
- Constant currency uEBITDA growth (+6%) demonstrating underlying earnings growth
- FX and weather were headwinds to reported performance but did not impact underlying earnings growth

## APAC

- Australia impacted by dry conditions early in the period – seasonal impact
- Growth in Asia, with Indonesia a key contributor – a structural driver of improved earnings. Adverse impact from currency translation

## North America

- 11% growth in uEBITDA in local currency
- Strong performance in Turf & Ornamental and Canada
- New product growth constrained by regulatory delays

## Europe

- 19% growth in uEBITDA driven by mix improvement and a sustainable reduction in costs, demonstrating structural margin improvement

1. In the 2025 financial year, the Group reallocated the seed treatment business such that it is now being reported within the Crop Protection operating regions, where it had previously been reported in the Seed Technologies segment. Comparative figures have been restated to reflect this change.

# Seed Technologies

Hybrid Seeds growth, repositioned Emerging Platforms with reduced capital requirements

SEED TECHNOLOGIES (\$m)	HY26	HY25 <sup>1</sup>	Change y/y
<b>Revenue</b>	243	215	13%
<b>uEBITDA</b>	58	27	113%
<b>uEBIT</b>	31	3	1124%
<b>Hybrid Seeds</b>			
Revenue	209	174	20%
uEBITDA	62	58	7%
<b>Emerging Platforms</b>			
Revenue	34	41	(16)%
uEBITDA	(4)	(30)	(88)%

## Hybrid Seeds

- uEBITDA +7% y/y was supported by favourable demand conditions for edible oils and renewable fuels
- Continuing expansion and scale-up in key South American markets. Strong growth in Australian canola
- Successful launch of new IMI-tolerant canola and sorghum varieties, strengthening our crop position

## Emerging Platforms

- uEBITDA improved \$26m y/y mainly reflecting omega-3
- Expansion of carinata oil offtake agreement with bp to support carinata growth at scale with a disciplined capital light investment model
- Omega-3 repositioning for future - cash costs reduced. First regulated trials for planting in Argentina. Deregulation for consumption in Japan achieved, with Europe and China on track for 2028

1. In the 2025 financial year, the Group reallocated the seed treatment business such that it is now being reported within the Crop Protection operating regions, where it had previously been reported in the Seed Technologies segment. Comparative figures have been restated to reflect this change.

# Financial Performance

Brendan Ryan



For personal use only

# Profit and Loss Summary

Strong growth in profitability driven by improved mix and cost discipline

NUF GROUP (\$m)	HY26	HY25	Change y/y
Revenue	1,714	1,811	(5)%
Underlying Gross profit	567	532	7%
Underlying Gross profit margin	33.1%	29.4%	3.7 ppt
Underlying Net operating expenses	(435)	(433)	1%
uEBITDA	243	206	18%
uEBIT	136	103	32%
EBIT	117	92	27%
Underlying Net financing cost	(57)	(48)	19%
Underlying Net Profit after Tax	52	38	35%
Statutory Net Profit after Tax	38	30	28%

- **Revenue lower** with increased focus on improving sales mix and quality
- **Gross profit growth** reflects improving Crop Protection mix, hybrid seeds growth and omega-3
- **Net operating expenses** benefiting from performance improvement program
- **Strong growth in uEBITDA and uEBIT** driven by gross profit improvement and flat operating expenses
- **Net financing costs** increased due to higher FX hedging costs with recent variability in currency markets
- **Strong growth in underlying and statutory NPAT**

Refer to Appendix 3 for non-IFRS definitions and disclosures

# Balance Sheet Summary

Strong reduction in leverage reflecting improving balance sheet efficiency and free cash flow

NUF GROUP (\$m)	HY26	HY25	Change y/y
Capex	66	148	(56)%
Net Working Capital	1,366	1,560	(12)%
Free Cash Flow	(439)	(632)	31%
aNWC to Sales %	37.1%	39.2%	(2.1) ppt
Net Debt	1,227	1,362	(10)%
Leverage	3.6x	4.5x	(0.9)x
ROFE excl. material Items	4.4%	3.2%	1.2 ppt

- **Reflects sustaining capital expenditure** following a period of peak investment, with favourable phasing contributing to improved cash generation
- **Continued focus on balance sheet efficiency**, reflected in a reduction in average net working capital
- **Net debt reduced 10% year on year**, after a \$190m higher opening balance entering FY26
- **Net leverage down 20% year on year**, reflecting disciplined capital management
- **ROFE improving from a relatively low base**, reflecting:
  - Initial benefits of increased strategic focus
  - Profit improvement in Seed Technologies


Refer to Appendix 3 for non-IFRS definitions and disclosures

# 2025 cost savings program

We are delivering on the 2025 cost savings program<sup>1</sup>

For personal use only

Cost savings achieved (\$m)



- **\$32m** cumulative
- Europe performance improvement program
- Reduction in commercial, portfolio and support spend
- On plan for \$50m savings by end of FY26
- **Outcome:** supports uEBITDA margin expansion and capital allocation discipline


1. Cost savings program announced at Nufarm's FY24 results



# Cash flow bridge

Cash flow improvement driven by improved profitability and disciplined capital management


## Cash Flow (\$m)



**Free cash flow improved by \$193m year on year**

- 1 Improved profitability** driving stronger operating cash flow
- 2 Disciplined working capital management**, with lower 1H net working capital outflows than pcp
- 3 Move to a lower capex envelope supporting cash generation**, with lower 1H partly benefiting from timing and phasing

## FCF year-on-year improvements (HY26 vs HY25)




# Net working capital

Continued year on year improvement in net working capital

Net Working Capital	HY26	HY25	Movement
Average Receivable Days (Sales)	91	98	7
Average Inventory Days (COGS)	193	188	(5)
Average Payable Days (COGS)	132	128	4
Net Days	153	159	6
Average NWC (\$m)	1,241	1,332	(7)%
Average NWC to Sales (%)	37.1%	39.2%	(2.1) ppt

- **6-day improvement in cash conversion cycle** primarily driven by reduction in receivables days
- **Temporarily higher inventory days** – Australian dry weather impacting volume
- **Continued y/y improvements in Average NWC** from 1H24 cyclical peak

Average NWC (\$m)




Average defined as the average monthly current inventory, receivables, payables and NWC for the twelve-month period

# Capital expenditure

Past peak capex in PP&E and have reduced capex in emerging platforms

Capital Expenditure (\$m)



## Capital expenditure focus

- Transitioning to sustaining capex following a period of peak investment
- More disciplined capital allocation, aligned to a refocused strategy
- Tighter prioritisation across the portfolio

## Drivers of y/y reduction:

- PP&E
  - Prior period included a higher level of manufacturing capex
  - Phasing of asset integrity works
- Intangibles
  - Yield 10 acquisition in pcp
  - Lower investment in the Omega-3 platform
  - Tighter prioritisation of portfolio spend
  - Portfolio spend weighted to 2H


## FY26 outlook:

- Targeting less than \$200m down from \$246m in the pcp


# Net debt

Continued improvements in Net Debt and Leverage

## Leverage



## Net Debt (\$m)



- **Leverage reduced 20% y/y**
- **Net debt \$135m below pcp**
- Reduction in Net debt and leverage driven by:
  - Improved **earnings**
  - Efficient management of **NWC**
  - Reduction in **capital expenditure**

# Strategy update and Outlook

Rico Christensen

For personal use only

# Strategy refresh

Sharper focus on where we win, capital-efficiency and profitable growth

For personal use only

**1 Capital prioritization and efficiency**

- ✓ Capital reprioritised to reflect more focused Crop Protection and Seeds strategies
- ✓ Selective asset & portfolio exits aligned with market priorities
- ✓ Alignment of cost base and capital spend with market footprint

**2 Improving Crop Protection quality of earnings and returns**

- ✓ More focused portfolio
- ✓ Capital reprioritisation towards markets where we can have a right to win
- ✓ Greater emphasis on value and margin
- ✓ Leveraging innovation through partnerships
- ✓ Profitable growth in chosen markets

**3 Two seeds platforms to grow and to focus capital deployment**

**Hybrid Seeds**

- ✓ Sorghum, canola, sunflower
- ✓ Core platform for growth with southern hemisphere focus

**Emerging Platforms**

- ✓ Carinata and Omega-3
- ✓ Disciplined investment to support growth and group returns



**Cash Flow**

**Margins**

**ROFE**

# Financial outcomes

We expect our strategy to deliver improved profitability, with higher returns and cash generation

For personal use only

## FY26/27 Targets<sup>1</sup>

### FY26

- \$50m cost savings<sup>2</sup> ✓ **On plan**
- Capex reset <\$200m FY26 (FY25 \$246m) ✓ **On plan**
- Leverage ~2.0x FY26 (FY25 2.7x) ✓ **On plan**

### FY27

- ✓ \$50m cost savings (announced in April 2026) – run rate savings by end FY27
- ✓ Capex sustained at similar level to FY26

## Through the Cycle Targets

- ✓ Positive free cash flow
- ✓ ROFE > cost of capital on average through the cycle
- ✓ aNWC to Sales 35-40%
- ✓ Leverage 1.5 – 2.0 times at FYE

1. Expected outcomes, subject to market conditions. 2. 2025 Cost Savings Program announced at FY24 result.

# April 2026 cost savings program

Our strategy refresh is highlighting new areas to reduce cost and improve efficiency.

For personal use only

## April-2026 cost savings program<sup>1</sup>

Cost Savings Focus	Implementation Costs	Timeline for Delivery
<ul style="list-style-type: none"><li>✓ Asset and portfolio rationalisation</li><li>✓ Operational efficiency and operating model</li><li>✓ ~60% COGS and ~40% SG&amp;A</li><li>✓ Initial Actions detailed on pages 20 &amp; 21</li></ul>	<ul style="list-style-type: none"><li>✓ \$15m cash implementation costs weighted to FY27</li></ul>	<ul style="list-style-type: none"><li>✓ Full run rate savings by the end of FY27</li><li>✓ Full benefit in FY28</li></ul>

1.. Cost savings program announced in April 2026

# Crop Protection

We are making changes to reflect our new focus

These actions are designed to redeploy capital to higher returning activities, reduce fixed cost, capital intensity and operational complexity, supporting higher and more resilient returns

## Crop Protection Focus

- ✓ More focused portfolio – cereals, soybeans and TNV plus regionally significant crops
- ✓ Capital reprioritisation towards markets where we can consistently earn returns above cost of capital
- ✓ Asset rationalisation to reflect portfolio and market priorities

## Initial Actions

### Portfolio

- |  |      |
|--|------|
| Investment re-prioritised with lower ongoing spend | FY26 |
| Portfolio rationalisation in North America         | FY26 |

### Site optimisation

- |   |           |
|---|-----------|
| Closure of Butyrics manufacturing unit at the Wyke site (UK)                | Announced |
| Closure and sale of the Kwinana site (Australia)                            | Announced |
| Further footprint options being assessed (office, warehouse, manufacturing) | Ongoing   |

### Operational efficiency

- |  |          |
|--|----------|
| Continuous improvement initiatives to deliver efficiency | Underway |
|--|----------|

# Seed Technologies changes

Seeds portfolio restructured to improve focus and capital discipline

## Seed Technologies Focus

- ✓ Aligned to reflect unique go to market, returns and capital requirements
- ✓ Grow hybrid seeds with southern hemisphere focus
- ✓ Grow carinata with bp
- ✓ Omega-3 – establish as a viable plant-based alternative to wild catch fishing

## Initial Actions

### Hybrid Seeds and Emerging Platforms

Organisational changes made

FY26

### Hybrid Seeds

European sunflower streamlined – move to licensing model

Underway

South America expansion

Underway

### Carinata

Oil offtake agreement with bp expanded to support ongoing growth

Done

### Omega-3

Reset to a lower level of cash spend

Done

Establish production in South America

Underway

Complete consumption deregulation. Japan achieved. Europe and China targeting FY28.

Underway

For personal use only

# Strategic priorities

We will continue to focus on delivering our strategic priorities.

## Priorities<sup>1</sup>

**Cost and capital discipline**

## Expectations for FY26 and FY27

- Deliver the April-2026 \$50m cost savings program
- Reset capex to disciplined envelope and strategy allocation framework
- Improve earnings quality and capital efficiency to lift free cash flow

**Drive profitable growth in Crop Protection**

- Shift portfolio mix to higher margin products
- Improve returns in US Crop Protection
- Continue margin and returns improvement in Europe

**Deliver on reprioritised Seeds strategy**

- Embed focused leadership and operating model
- Prioritise Hybrid Seeds in the southern hemisphere
- Align investment to return-led growth

1. Refer to Nufarm FY25 Full Year Result, page 22, FY26 Priorities

# FY26 Outlook

We reaffirm our uEBITDA and leverage outlook for FY26.

- **Expecting strong growth in uEBITDA in FY26, assuming normal seasonal and market conditions**
  - Positive momentum continued in April and May
  - Continuing to manage increases in the cost of Active Ingredients , freight and energy arising from instability in the Middle East
- **Net debt and leverage expected to reduce**
  - Targeting leverage approximately 2.0x Net debt/uEBITDA by end of FY26 (FY25 2.7)
  - Expect positive free cash flow in FY26, driven by the normal historical seasonal unwind in working capital
  - Targeting capital expenditure <\$200m
- **Crop Protection**
  - Continuing growth in uEBITDA, improving on 1H growth rate, driven by continuing margin improvement and delivery of cost savings
- **Seed Technologies**
  - Strong growth in uEBITDA from Hybrid Seeds
  - Expecting a \$40m improvement in uEBITDA from Emerging Platforms, resulting from our expanded carinata offtake agreement with bp and improvement in omega-3

# Q&A



# Appendices

For personal use only

# Appendix 1 : Segment information and reconciliation

For personal use only

	6 months ended 31 Mar 2026	Restated 6 months ended 31 Mar 2025	Change	Change
Revenue - Underlying (\$000)	\$000	\$000	\$000	%
<i>Crop Protection</i>				
APAC	403,086	460,682	(57,596)	(13%)
North America	583,239	637,939	(54,700)	(9%)
Europe	484,627	497,548	(12,921)	(3%)
<b>Total Crop Protection</b>	<b>1,470,952</b>	<b>1,596,169</b>	<b>(125,217)</b>	<b>(8%)</b>
Seed Technologies	243,365	214,712	28,653	13%
Corporate	-	-	-	-
<b>Nufarm Group</b>	<b>1,714,317</b>	<b>1,810,881</b>	<b>(96,564)</b>	<b>(5%)</b>
EBITDA - Underlying (\$000)	6 months ended 31 Mar 2026 \$000	Restated 6 months ended 31 Mar 2025 \$000	Change \$000	Change %
<i>Crop Protection</i>				
APAC	55,475	65,394	(9,919)	(15%)
North America	54,871	55,578	(707)	(1%)
Europe	113,014	95,301	17,713	19%
<b>Total Crop Protection</b>	<b>223,360</b>	<b>216,273</b>	<b>7,087</b>	<b>3%</b>
Seed Technologies	58,159	27,332	30,827	113%
Corporate	(38,783)	(37,709)	(1,074)	3%
<b>Nufarm Group</b>	<b>242,736</b>	<b>205,896</b>	<b>36,840</b>	<b>18%</b>
EBIT - Underlying (\$000)	6 months ended 31 Mar 2026 \$000	Restated 6 months ended 31 Mar 2025 \$000	Change \$000	Change %
<i>Crop Protection</i>				
APAC	47,396	56,489	(9,093)	(16%)
North America	35,831	35,430	401	1%
Europe	63,911	48,042	15,869	33%
<b>Total Crop Protection</b>	<b>147,138</b>	<b>139,961</b>	<b>7,177</b>	<b>5%</b>
Seed Technologies	30,661	2,506	28,155	1124%
Corporate	(41,981)	(39,731)	(2,250)	6%
<b>Nufarm Group</b>	<b>135,818</b>	<b>102,736</b>	<b>33,082</b>	<b>32%</b>

	6 months ended 31 Mar 2026	Restated 6 months ended 31 Mar 2025	Change	Change
(\$000)	\$000	\$000	\$000	%
<b>Europe (EUR)</b>				
Revenue	283,030	299,517	(16,487)	(6%)
EBITDA - Underlying	66,656	56,993	9,663	17%
EBIT - Underlying	38,308	28,360	9,948	35%
<b>North America (USD)</b>				
Revenue	397,303	407,273	(9,970)	(2%)
EBITDA - Underlying	38,670	34,878	3,792	11%
EBIT - Underlying	25,855	21,943	3,912	18%

In the 2025 financial year, the Group updated its operating segment structure. As a result, the seed treatment business is now reported within the Crop Protection operating regions rather than the Seed Technologies segment. Comparative figures have been restated to reflect this change.

# Appendix 2 : underlying and statutory profit

	6 months ending 31 Mar 2026			6 months ending 31 Mar 2025		
	Underlying \$000	Material items \$000	Total \$000	Underlying \$000	Material items \$000	Total \$000
<b>Revenue</b>	<b>1,714,317</b>	-	<b>1,714,317</b>	<b>1,810,881</b>	-	<b>1,810,881</b>
Cost of sales	(1,147,085)	(2,259)	(1,149,344)	(1,278,605)	(7,648)	(1,286,253)
<b>Gross profit</b>	<b>567,232</b>	(2,259)	<b>564,973</b>	<b>532,276</b>	(7,648)	<b>524,628</b>
Sales, marketing and distribution expenses	(297,777)	(221)	(297,998)	(289,593)	261	(289,332)
General and administrative expenses	(103,070)	(16,122)	(119,192)	(108,994)	(2,903)	(111,897)
Research and development expenses	(34,258)	(327)	(34,585)	(34,012)	(474)	(34,486)
<b>Operating expenses</b>	<b>(435,105)</b>	<b>(16,670)</b>	<b>(451,775)</b>	<b>(432,599)</b>	<b>(3,116)</b>	<b>(435,715)</b>
Other income	3,691	-	3,691	3,059	-	3,059
<b>Operating profit</b>	<b>135,818</b>	<b>(18,929)</b>	<b>116,889</b>	<b>102,736</b>	<b>(10,764)</b>	<b>91,972</b>
D&A	(106,918)	(108)	(107,026)	(103,160)	-	(103,160)
<b>EBITDA</b>	<b>242,736</b>	<b>(18,821)</b>	<b>223,915</b>	<b>205,896</b>	<b>(10,764)</b>	<b>195,132</b>
<b>Share of net profits/(losses) of associates</b>	<b>119</b>	-	<b>119</b>	<b>(429)</b>	-	<b>(429)</b>
Net interest expenses	(47,007)	-	(47,007)	(48,816)	-	(48,816)
Net foreign exchange gains/(losses)	(10,003)	-	(10,003)	733	-	733
<b>Net financing costs</b>	<b>(57,010)</b>	-	<b>(57,010)</b>	<b>(48,083)</b>	-	<b>(48,083)</b>
<b>Profit before tax</b>	<b>78,927</b>	<b>(18,929)</b>	<b>59,998</b>	<b>54,224</b>	<b>(10,764)</b>	<b>43,460</b>
Income tax benefit/(expense)	(26,835)	5,035	(21,800)	(15,759)	2,050	(13,709)
<b>Profit for the period</b>	<b>52,092</b>	<b>(13,894)</b>	<b>38,198</b>	<b>38,465</b>	<b>(8,714)</b>	<b>29,751</b>
Profit/(loss) from discontinued operation, net of tax	-	-	-	-	-	-
<b>Profit for the period</b>	<b>52,092</b>	<b>(13,894)</b>	<b>38,198</b>	<b>38,465</b>	<b>(8,714)</b>	<b>29,751</b>

For personal use only

# Appendix 3 : Non-IFRS disclosures & definitions


For personal use only

Term	Definitions
Gross profit margin	Gross profit as a percentage of revenue
Underlying gross profit	Gross profit excluding the impact of material items
Underlying gross profit margin	Underlying gross profit as a percentage of revenue
Underlying net operating expenses	Sales, marketing and distribution expenses plus general and administrative expenses plus research and development expenses, excluding the impact of material items
Underlying EBIT	Earnings before net financing costs, taxation, share of net profits/(losses) of equity accounted investees and excluding the impact of material items
Underlying EBITDA	Underlying EBIT before depreciation and amortisation and excluding the impact of material items
Underlying net profit after tax	Profit/(loss) for the period attributable to the equity holders of Nufarm Limited, excluding the impact of material items
Capex	Capital expenditure on property, plant and equipment, intellectual property and development costs, and other investments
Net Working Capital	Current trade and other receivables, plus inventories less current trade and other payables
aNWC to sales (%)	Average net working capital as a percentage of rolling 12 months revenue
Net debt	Current loans and borrowings, plus non-current loans and borrowings, less cash and cash equivalents
Net debt excluding leases	Net debt less lease liabilities
Leverage	Net debt / rolling 12 months underlying EBITDA
Return on funds employed (ROFE)	12 months rolling EBIT divided by the average of opening and closing funds employed (total equity plus net debt)
Return on funds employed (ROFE) excluding material items	12 months rolling underlying EBIT divided by the average of opening and closing funds employed (total equity plus net debt)
Emerging Platforms	Comprises the Omega-3 and platforms within the Seed Technologies operating segment
Constant currency	Financial results assuming constant foreign currency exchange rates used for translation based on the rates in effect for the comparable prior-year period.

# Appendix 4: Revenue bridge

Revenue reflects mix and margin focus

For personal use only



- Revenue lower with sales and mix focused on improving portfolio quality
- Modest benefit from price and headwind from currency translation
- Growth in Seed Technologies driven by Canola and Sunflower

<sup>1</sup> In the 2025 financial year, the Group updated its operating segment structure. As a result, the seed treatment business is now reported within the Crop Protection operating regions rather than the Seed Technologies segment. Comparative figures have been restated to reflect this change.




# Appendix 5: Debt maturity profile

Flexible funding with headroom provided by undrawn facilities and cash

For personal use only

Gross Debt<sup>1</sup> drawn and headroom (\$m)



Principal Debt Facilities Available (\$m)	Limit	Maturity
High Yield USD Bond	\$350 US	Jan-30
Asset Based Lending (ABL) Facility	\$800	Nov-27
Standby Liquidity Facility (SLF) <sup>2</sup>	\$210	Nov-26/27
Amortising Loan Facility (ALF) <sup>3</sup>	\$90	Sep-27
Other facilities	\$222	Various

1. Debt presented in this graph excludes leases. Refer to Appendix 1 for non-IFRS definitions and disclosures  
 2. \$160m maturing November 2027, and \$50m maturing November 2026.  
 3. \$45m repayment due in both September 2026 and September 2027

# Appendix 6: Seed Technologies highlights

We are accelerating adoption of our proprietary hybrids leveraging our IP and strong southern hemisphere position

For personal use only

## Innovation rate<sup>1</sup>: 12% of Sales




**Canola - First to market herbicide tolerance unlocking structural growth**  
Extending technology leadership in South America as the first to introduce IMI tolerant hybrids across Brazil, Argentina, Paraguay and Uruguay, and with a recent launch in Brazil of the market's first IMI plus Triazine Tolerant hybrid, positioning us to capture value as canola area expands on structural demand from edible oils, renewable fuels and new crushing capacity.

3-year sales CAGR  
South America: **57%**



**Sorghum - Proprietary hybrids accelerating adoption in second season systems**  
Product adoption is accelerating in Brazil, with Nufarm's new variety introductions ramping faster than prior launches due to early maturity, strong yield stability and fit with second season planting windows. IMI tolerant sorghum continues to gain traction as growers prioritise improved weed control and resistance management.

3-year sales CAGR  
South America : **(4)%**



**Sunflower - New genetics driving relevance, share and commercial momentum in Argentina**  
Portfolio freshness is a key advantage, supporting continued share gains as newer, higher performing genetics replace older varieties and convert pipeline investment into commercial impact.

3-year sales CAGR  
South America: **30%**

1. Innovation rate: Contribution from varieties launched over the last three-year period.

# Appendix 7: Crop Protection highlights

Our solutions target real world problems to create tangible value for growers.

## Innovation Rate<sup>1</sup>: 13% of Sales



### Expanding our Duplosan<sup>®</sup> powered herbicides

Incorporating Dichlorprop-p to target herbicide resistant weeds such as Koicha in North America. Launched in Canada in FY24 under the Oxbow<sup>®</sup> and Blackhawk EVO<sup>®</sup> brands and Scorch EXT<sup>®</sup> in Colorado, Kansas and Texas in the USA. Launching as Armatus<sup>®</sup> in Europe, a dual mode of action herbicide targeting a broad range of weeds in spring and winter cereals.

- US\$200m Market Opportunity
- 3-year sales CAGR: **44%**
- Gross margin above group average



**Growing our biologicals portfolio. Trunemco<sup>®</sup>** is a biological seed-treatment offering broad spectrum nematode protection in corn, soybean and cotton and experiencing rapid growth in the Americas.

- US\$270m Market Opportunity
- 3-year sales CAGR: **46%**
- Gross margin significantly above group average



In Europe, Nufarm is partnering with Agrauxine for distribution of a new BioFungicide called **Nuxine<sup>®</sup>**, strengthening our **biologicals pipeline**. The active ingredient Cerevisane (active ingredient) is a natural, yeast-based agricultural fungicide (biocontrol agent) derived from the cell walls of *Saccharomyces cerevisiae* strain.

- New to market






1. Innovation rate: Contribution from products launched over the last five-year period.

For personal use only



# Appendix 9: FY26 Portfolio Solutions Key Milestones & Updates

For personal use only

 Foundational Solutions	 Innovative Solutions	 Biological Solutions	 Emerging Solutions	 Integrated Solutions
<p><b>Joust®/Joust Pro® in Europe</b></p> <ul style="list-style-type: none"> <li>✓ Joust Pro registered in Poland, Turkey and France, and Joust in Denmark and Estonia</li> </ul> <p><b>Cruzade ® in Canada</b></p> <ul style="list-style-type: none"> <li>✓ Registration on cereals provide new option for broad spectrum disease control</li> </ul> <p><b>Carnadine®</b></p> <ul style="list-style-type: none"> <li>✓ Registrations in UK and Finland, emergency authorization in Austria, and label extensions in Poland and Lithuania</li> </ul> <p><b>OpteraPro® and NaxyPro™</b></p> <ul style="list-style-type: none"> <li>✓ Registrations in Romania and Czech Rep.</li> <li>✓ NaxyPro™ and OpteraPro™ insecticides approved for use in T&amp;O and crop protection in USA</li> </ul> <p><b>Portfolio expansion in Asia</b></p> <ul style="list-style-type: none"> <li>✓ Launched Nando® fungicide and Dictate® herbicide in Vietnam, and Xenon® insecticide in Indonesia</li> </ul>	<p><b>Terrad'or® new markets</b></p> <ul style="list-style-type: none"> <li>✓ Label extension on wheat in Australia and additional pack-size in Indonesia open new market segments for tiafenacil</li> </ul> <p><b>Teppan® in APAC</b></p> <ul style="list-style-type: none"> <li>✓ Launch in Vietnam, registration approval in Malaysia, and label extension in Australia to control key pests in tree fruits and vegetables</li> </ul> <p><b>Curator™ in USA</b></p> <ul style="list-style-type: none"> <li>✓ Curator™ launched in T&amp;O to control pythium, one of the most devastating diseases to golf course turf.</li> </ul>	<p><b>Simpell® expands in Europe</b></p> <ul style="list-style-type: none"> <li>✓ Registrations in Belgium, Spain and Montenegro, and emergency uses on tree crops in Spain</li> </ul> <p><b>Exsolant™, Exsolant XHL and Simpell™ brand family launched in US</b></p> <ul style="list-style-type: none"> <li>✓ Launch of naturally derived biological insecticides for use in specialty, row crops, and T&amp;O</li> </ul> <p><b>Strengthening Europe's Biological portfolio</b></p> <ul style="list-style-type: none"> <li>✓ Nuxine® registration in Austria</li> </ul> <p><b>Botector® new uses in New Zealand</b></p> <ul style="list-style-type: none"> <li>✓ Label extension for the control of key disease Psa in kiwifruit</li> </ul> <p><b>Trunemco® Label Expansion in USA and launch of Evolvance® in Brazil</b></p> <ul style="list-style-type: none"> <li>✓ Expanded label for Nufarm's bionematicide to include Cereals, Vegetables, and other specialty crops, and launch of new brand in Brazil</li> </ul>	<p><b>First sales of Kilter AX-1</b></p> <ul style="list-style-type: none"> <li>✓ Completed first commercial sales in Australia by Croplands. Further research and development trials have commenced under a collaboration with Hort Innovation</li> </ul> <p><b>Green-on-green collaboration</b></p> <ul style="list-style-type: none"> <li>✓ Continuing collaboration with Croplands and Grains Research &amp; Development Corporation to evaluate three non-OEM Green-on-Green technology partners in Australian conditions. Currently focused on development in wheat, barley and canola to selectively spray emerged weeds.</li> </ul>	<p><b>Evolvance® and Sorpro® on Nufarm Seed technologies sorghum in Brazil</b></p> <ul style="list-style-type: none"> <li>✓ Nufarm's bionematicide Evolvance® and herbicide safener Sorpro® have been incorporated in the sorghum ST package in Brazil</li> </ul>

© Botector is a registered trademark of SAN Agrow Holding GmbH'. © Terrad'or is a registered trademark of FarmHannong Co., Ltd. © Teppan is a registered trademark of Ishihara Sangyo Kaisha, Ltd.

# Thank you

For personal use only

